Accumetrics has received Health Canada license for its VerifyNow system, designed to measure platelet reactivity in patients on antiplatelet medications including aspirin and P2Y12 inhibitors (clopidogrel).
As per the license, VerifyNow system is now available to hospitals and clinical laboratories in Canada.
In addition, Accumetrics has signed an agreement with Force 3 Medical for distribution of the VerifyNow system in Canada.
Accumetrics president and CEO Timothy Still said, "Achieving a Health Canada license is another important milestone in our mission to provide patients and healthcare professionals the highest quality clinical evidence that allows for improved management of cardiovascular disease throughout the world."
Force 3 Medical president and CEO Gilbert Pommepuy said the VerifyNow system is being used in the Prospective Randomized ON-X Valve Anticoagulation Clinical Trial study, and the four Canadian contributing centers have been impressed with its usefulness in managing patients' antiplatelet treatment strategies.
"We are very excited at the prospect of being able to expand the use of the VerifyNow System and making it a new standard of care," Pommepuy added.
